10 Merck AI and data science leaders

Merck's AI and data science bench here is weighted toward commercial work, with four people on commercial data science, generative AI and AI agents. The rest cover AI methods and models, research data science platforms, generative AI for quality and labs, enterprise AI portfolio strategy, and machine learning for protein engineering, now former. Two joined Merck in 2026 from Microsoft and Applied Intelligence. Pharma AI teams can compare how each area sets priorities.

10 professionals1 companyData retrieved October 15, 2026

Professionals to explore

  1. Andrew B. Waight

    LinkedIn

    Experience: Former Sr. Director, ML Engineering & Protein Engineering · Merck

    $673 per 30-minute call

    Andrew B. Waight was Sr. Director, ML Engineering & Protein Engineering at Merck (2023-2026) and Principal Scientist - Protein Sciences & Developability there (2020-2023). Andrew was also Principal Scientist - Protein Engineering & Antibody Discovery at SystImmune (2019-2020) and Senior Scientist - Protein Sciences & Computational Drug Design at Seagen (2013-2019). Andrew fits questions on applying machine learning to antibody and protein design.

    Is this you? Claim your profile and get paid for calls.

  2. Andrew E. Noble

    LinkedIn

    Experience: Director, Data Science, AI/ML Platform/Methodology Lead · Merck

    $606 per 30-minute call

    Andrew E. Noble is Director, Data Science, AI/ML Platform/Methodology Lead at Merck (since 2024), in the research department. Andrew was Director, Data Science at Quest Diagnostics (2023-2024) and Senior Principal Data Scientist and Machine Learning Engineer at ConcertAI (2021-2023) and Dana-Farber Cancer Institute (2020-2021). Andrew suits questions on building shared machine learning platforms for research teams.

    Is this you? Claim your profile and get paid for calls.

  3. Blue Alozie

    LinkedIn

    Experience: Director, AI Innovation Studios (US) · Merck

    $606 per 30-minute call

    Enterprise AI portfolio prioritization and sequencing investments, plus operating model and transformation governance across global business units, are what Blue Alozie owns as Director, AI Innovation Studios (US) at Merck since December 2025. Earlier Merck titles include Director, India Tech Center Digital HH Community Lead & AI Practice Lead (2025) and Associate Director, Investor Relations (2022-2023). Blue fits questions on deciding which AI investments go first.

    Is this you? Claim your profile and get paid for calls.

  4. Eric T. Carlson

    LinkedIn

    Experience: Executive Director, Global Data Science, Digital Solutions Product Owner · Merck

    $1,010 per 30-minute call

    Eric T. Carlson has been Executive Director, Global Data Science, Digital Solutions Product Owner at Merck since 2021, serving as Commercial AI & Decision Support Solutions Lead. Eric was Vice President, Quantitative Investment Strategies at Goldman Sachs (2017-2021) and Senior Scientist at Philips (2013-2017), working on AI for patient care. Eric suits questions on decision support tools for commercial teams.

    Is this you? Claim your profile and get paid for calls.

  5. James Arnold PhD

    LinkedIn

    Experience: Former Director, Data Science and Artificial Intelligence · Merck

    $606 per 30-minute call

    Since April 2026, James Arnold has been Director, Data Science and Artificial Intelligence at Merck, after Head of Artificial Intelligence and Machine Learning at Applied Intelligence (2024-2026). At Genentech, James was Director of Artificial Intelligence and Data Science (2021-2023) and Director, Artificial Intelligence Strategy (2020-2021), and earlier US Lead Artificial Intelligence Healthcare & Life Science at Accenture. James fits questions on AI strategy, drawing on the Genentech and Accenture roles.

    Is this you? Claim your profile and get paid for calls.

  6. Kristen Severson

    LinkedIn

    Experience: Former Director, AI Methods and Models · Merck

    $606 per 30-minute call

    Research roles at Microsoft and IBM came ahead of Kristen Severson's start as Director, AI Methods and Models at Merck in September 2026: Principal Researcher (2025-2026) and Senior Researcher (2021-2025) at Microsoft, and Research Staff Member and Postdoctoral Researcher at IBM (2018-2021). With that research record, Kristen can speak to choosing AI methods and model approaches for a new Merck team.

    Is this you? Claim your profile and get paid for calls.

  7. Luis A. Adrianza

    LinkedIn

    Experience: Executive Director, AI Business Engagement & Innovation · Merck

    $841 per 30-minute call

    Embedding AI and generative AI across the company is the work Luis A. Adrianza describes as Executive Director, AI Business Engagement & Innovation at Merck since November 2025 and Commercial Generative AI & Automation Lead since 2024. Luis was Digital Marketing & Content Strategy Director at Merck (2020-2024) and held platform and product roles at MSD Czech Republic (2017-2020). Ask Luis about getting business teams to adopt AI.

    Is this you? Claim your profile and get paid for calls.

  8. Manisha Bhardwaj

    LinkedIn

    Experience: Director, Generative AI - Digital Quality & Labs, Digital MMD · Merck

    $640 per 30-minute call

    Generative AI for quality and labs is the remit in Manisha Bhardwaj's title, Director, Generative AI - Digital Quality & Labs, Digital MMD at Merck since 2023. Manisha was Senior Data Science Manager at Walmart Global Tech (2022-2023) and, at Halliburton, Distinguished Data Scientist Data Science Advisor - Landmark (2020-2022) and Head of Data Science Data Science Advisor - Production Enhancement (2017-2020). Manisha is the one to ask about generative AI in quality and lab work.

    Is this you? Claim your profile and get paid for calls.

  9. Ritu Saxena, Ph.D

    LinkedIn

    Experience: Director, Pharmaceutical Commercial AI Agents · Merck

    $673 per 30-minute call

    Evaluating generative AI tools for business strategy and ROI was part of Ritu Saxena's work as Director Analytics Strategy & Data Science at Merck (2022-2026), ahead of the current title, Director, Pharmaceutical Commercial AI Agents, since March 2026. Ritu was also Associate Director, Global Oncology Data & Analytics at Merck (2021-2022) and Associate Director, Enterprise Analytics at Astellas Pharma US (2019-2021). Ritu suits questions on AI agents for commercial pharma work.

    Is this you? Claim your profile and get paid for calls.

  10. Smita Mitra

    LinkedIn

    Experience: Executive Director, Head of Commercial Data Science & GenAI · Merck

    $1,010 per 30-minute call

    Executive Director, Head of Commercial Data Science & GenAI at Merck since January 2025, Smita Mitra was Director, Commercial Data Science at Johnson & Johnson Innovative Medicine (2021-2024) and held Principal Scientist, Machine Learning & Advanced Algorithms (2016-2021) and Associate Director, Text Analytics (2014-2016) roles at Janssen. Smita fits questions on commercial data science and generative AI for a pharma sales and marketing organization.

    Is this you? Claim your profile and get paid for calls.

Choose the right perspective

For commercial AI, talk to Smita Mitra, Luis A. Adrianza, Eric T. Carlson or Ritu Saxena. AI methods, data science platforms and research questions point to Kristen Severson, James Arnold, Andrew E. Noble or, for biologics, Andrew B. Waight; Manisha Bhardwaj covers generative AI in quality and labs, and Blue Alozie how enterprise AI investments are prioritized.

Questions to take into the conversation

  1. 01How does Merck rank AI projects across commercial, research and manufacturing when they compete for the same budget and engineers?
  2. 02What validation does a generative AI tool need before quality or lab teams can rely on it in regulated work?
  3. 03How would you measure whether commercial AI agents are actually helping pharma sales and marketing teams at Merck?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Other perspectives in Pharmaceuticals